3,4-二氨基吡啶

Description

3,4-Diaminopyridine · CAS 54-96-6 · C5H7N3. UNII RU4S6E2G0J. Melting Point: 229; LogP: -0.5.

Identification

CAS Registry Number	54-96-6
PubChem CID	5918
Molecular formula	C5H7N3
IUPAC name	pyridine-3,4-diamine
UNII (FDA)	RU4S6E2G0J

Computed Descriptors

Molecular Weight	109.13
XLogP3	-0.5
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	0
Exact Mass	109.063997236
Monoisotopic Mass	109.063997236
Topological Polar Surface Area	64.9
Heavy Atom Count	8
Formal Charge	0

Physical & Chemical Properties

Melting Point	229
LogP	-0.5

Physical description & handling notes

• freely soluble in water, and slightly soluble in solvents ethanol, methanol and acetic acid
• 12.2 [ug/mL] (The mean of the results at pH 7.4)

GHS Hazard Classification

Reported hazard statements	H300 (94.2%), H311 (86.5%), H315 (86.5%), H319 (98.1%), H330 (94.2%), H335 (82.7%)

Documented Uses

• Amifampridine is indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients. Nevertheless, at the current time only the Firdapse brand of amifampridine is indicated for the treatment of LEMS in both adult and pediatric patients, while the Ruzurgi brand of amifampridine is indicated for the treatment of LEMS only in patients aged 6 to less than 17 years.
• Amifampridine is an orally available potassium channel blocker that increases acetylcholine in synaptic clefts of peripheral nerve endings and is used to treat the Lambert-Eaton myasthenic syndrome. Amifampridine is associated with a low rate of transient serum enzyme elevations during therapy but has not been linked with instances of clinically apparent acute liver injury.
• Breastfeeding; Lactation; Neuromuscular Agents; Potassium Channel Blockers;
• Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
• A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS.
• Established Pharmacologic Class [EPC] - Potassium Channel Blocker

Synonyms

3,4-DIAMINOPYRIDINE; pyridine-3,4-diamine; 54-96-6; Amifampridine; 3,4-Pyridinediamine; 3,4-DAP; 4,5-Diaminopyridine; Pyridine, 3,4-diamino-; SC10; 3,4 Diaminopyridine; amifampridina; DTXSID6046715; RU4S6E2G0J; NSC-521760; DTXCID4026715; 5-22-11-00266 (Beilstein Handbook Reference)

Frequently Asked Questions

What are the CAS number and molecular formula of 3,4-Diaminopyridine?

CAS 54-96-6; molecular formula C5H7N3; molecular weight — g/mol.

What other names is 3,4-Diaminopyridine known by?

3,4-DIAMINOPYRIDINE, pyridine-3,4-diamine, 54-96-6, Amifampridine, 3,4-Pyridinediamine, 3,4-DAP.

Is 3,4-Diaminopyridine classified as hazardous?

Hazard statements reported: H300, H311, H315, H319, H330.

What are the key physical properties of 3,4-Diaminopyridine?

Melting Point: 229; LogP: -0.5.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.